News | Radiation Therapy | January 03, 2017

NCCN Guidelines Recommend Y-90 Microspheres for Metastatic Colorectal Cancer Treatment

Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres

January 3, 2017 — Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.

The new NCCN Guidelines are available online at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

According to Sirtex Americas CEO Kevin Richardson, the company has positive signals in the first-line setting from the results to-date of the SIRFLOX study1 and expects results from the SIRFLOX, FOXFIRE and FOXFIRE Global studies in the first half of 2017.

These findings are also supported by the landmark MORE study2, a large retrospective analysis conducted in the United States with SIR-Spheres Y-90 resin microspheres in more than 600 mCRC patients. The MORE study helped to increase the understanding of SIRT as a treatment option for patients who have failed multiple lines of chemotherapy, while highlighting the positive aspects of the safety and efficacy of the protocol for patients of all ages.

“Clinical research has shown that SIRT brings patients with colorectal liver metastases improved and prolonged quality of life,” said lead investigator of the MORE study, Andrew S. Kennedy, M.D., FACRO, director, radiation oncology research at Sarah Cannon Research Institute, Nashville, Tenn. “We look forward to expanding access to this outpatient procedure, which has demonstrated minimal side effects, to improve outcomes for this population of patients and advance the standard of care.”

SIR-Spheres Y-90 resin microspheres are the first and only microspheres with U.S. Food and Drug Administration (FDA) premarket approval (PMA) for colorectal cancer that has metastasized to the liver.3

For more information, visit www.sirtex.com.

References

1. van Hazel GA, Heinemann V, Sharma NK et al. SIRFLOX: Randomized Phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2016; 34: 1723–1731.

2. Kennedy AS, Ball D, Cohen SJ et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. Journal of Gastrointestinal Oncology. 2015; 6: 134–142

3. SIR-Spheres microspheres (Yttrium-90 Microspheres) Product Information. Available at: www.sirtex.com/us/clinicians/package-insert/. Assessed on December 8, 2016.

 

Related Content

New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
RaySearch and MD Anderson Collaborate on Development of RayCare
News | Oncology Information Management Systems (OIMS) | April 18, 2017
The University of Texas MD Anderson Cancer Center in Houston, Texas, will collaborate with RaySearch on the development...
New ASTRO Guideline Establishes Standard of Care for Curative Oropharyngeal Cancer Treatment With Radiotherapy
News | Radiation Therapy | April 17, 2017
April 17, 2017 — The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the mana
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new...
radiotherapy, radiation therapy, CHLA, Children's Hospital Los Angeles study, young children, brain tumors, outcomes, Pediatric Blood & Cancer

Image courtesy of CHLA.

News | Radiation Therapy | April 06, 2017
A team of investigators has determined that young children participating in a clinical trial to assess the...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville,...
Mevion, S250i proton therapy system, Hyperscan pencil beam scanning, installation, MedStar Georgetown University Hospital
News | Proton Therapy | April 04, 2017
April 4, 2017 — Mevion Medical Systems announced the installation of the first Mevion S250i...
high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017
EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity...
News | Radiopharmaceuticals and Tracers | March 29, 2017
Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in...
Overlay Init